ECSP17045054A - Derivados de fumagilol - Google Patents

Derivados de fumagilol

Info

Publication number
ECSP17045054A
ECSP17045054A ECIEPI201745054A ECPI201745054A ECSP17045054A EC SP17045054 A ECSP17045054 A EC SP17045054A EC IEPI201745054 A ECIEPI201745054 A EC IEPI201745054A EC PI201745054 A ECPI201745054 A EC PI201745054A EC SP17045054 A ECSP17045054 A EC SP17045054A
Authority
EC
Ecuador
Prior art keywords
compounds
stereoisomers
formula
disorders
fumagillol derivatives
Prior art date
Application number
ECIEPI201745054A
Other languages
English (en)
Inventor
Christopher Mcbride
John David Lawson
Zacharia Cheruvallath
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of ECSP17045054A publication Critical patent/ECSP17045054A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se divulgan los compuestos de Fórmula 1, (descrita en archivo adjunto a la presente solicitud),estereoisómeros de estos y sales farmacéuticamente aceptables de los compuestos y estereoisómeros, donde R1 y R2 se definen en la especificación. Esta descripción también se refiere a los materiales y métodos para preparar los compuestos de Fórmula 1, a las composiciones farmacéuticas que los contienen y a su uso para tratar la obesidad y enfermedades relacionadas, trastornos y desórdenes relacionados con MetAP2.
ECIEPI201745054A 2014-12-19 2017-07-12 Derivados de fumagilol ECSP17045054A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462094823P 2014-12-19 2014-12-19

Publications (1)

Publication Number Publication Date
ECSP17045054A true ECSP17045054A (es) 2017-10-31

Family

ID=55071249

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201745054A ECSP17045054A (es) 2014-12-19 2017-07-12 Derivados de fumagilol

Country Status (25)

Country Link
US (2) US9827255B2 (es)
EP (1) EP3233870B1 (es)
JP (1) JP2018500329A (es)
KR (1) KR20170099973A (es)
CN (1) CN107207547A (es)
AR (1) AR103078A1 (es)
AU (1) AU2015364477A1 (es)
BR (1) BR112017012965A2 (es)
CA (1) CA2971282A1 (es)
CL (1) CL2017001602A1 (es)
CO (1) CO2017007189A2 (es)
CR (1) CR20170332A (es)
DO (1) DOP2017000138A (es)
EA (1) EA032431B1 (es)
EC (1) ECSP17045054A (es)
ES (1) ES2702026T3 (es)
IL (1) IL252908A0 (es)
MX (1) MX2017007926A (es)
PE (1) PE20171141A1 (es)
PH (1) PH12017501134A1 (es)
SG (1) SG11201704985VA (es)
TN (1) TN2017000254A1 (es)
TW (1) TW201636342A (es)
UY (1) UY36450A (es)
WO (1) WO2016100778A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201636342A (zh) 2014-12-19 2016-10-16 武田藥品工業有限公司 煙黴醇衍生物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH26256A (en) 1988-08-12 1992-04-01 Fujisawa Pharmaceutical Co Oxaspiro [2,5] octane derivative
EP0682020A1 (en) 1988-09-01 1995-11-15 Takeda Chemical Industries, Ltd. Fumagillol derivatives useful as angiogenesis inhibitors
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
JPH1081631A (ja) * 1996-07-17 1998-03-31 Takeda Chem Ind Ltd 癌転移または再発抑制剤
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
WO1998056372A1 (en) 1997-06-09 1998-12-17 Massachusetts Institute Of Technology TYPE 2 METHIONINE AMINOPEPTIDASE (MetAP2) INHIBITORS AND USES THEROF
AU3352799A (en) 1997-10-31 1999-08-23 Children's Medical Center Corporation Method for regulating size and growth of vascularized normal tissue
KR100357541B1 (ko) 1998-05-15 2002-10-18 주식회사종근당 5-데메톡시 푸마질롤 유도체 및 그 제조방법
KR100357542B1 (ko) * 1998-05-15 2002-10-18 주식회사종근당 푸마질롤 유도체 및 그 제조방법
PL366216A1 (en) 2000-11-01 2005-01-24 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
WO2003027104A1 (en) 2001-09-27 2003-04-03 Idrtech Inc. Fumagillol derivatives and preparing method thereof
WO2003086382A1 (en) 2002-04-11 2003-10-23 Children's Medical Center Corporation Tnp-470 polymer conjugates and use thereof
KR100552043B1 (ko) 2004-02-28 2006-02-20 주식회사종근당 푸마질롤 유도체를 포함하는 비만치료용 조성물
CA2594951A1 (en) * 2005-01-26 2006-08-03 Chong Kun Dang Pharmaceutical Corp. Fumagillol derivatives or method for preparation of fumagillol derivatives, and pharmaceutical compositions comprising the same
FR2886855B1 (fr) 2005-06-08 2009-07-17 Agronomique Inst Nat Rech Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques
MX2010005857A (es) 2007-11-28 2010-11-22 Mersana Therapeutics Inc Conjugados de analogos de fumagillina biodegradables biocompatibles.
US8299067B2 (en) 2008-03-27 2012-10-30 Versitech Limited 5-demethoxyfumagillol and derivatives thereof
WO2010065877A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
WO2010065883A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Method of treating an overweight or obese subject
JP2013527157A (ja) * 2010-04-15 2013-06-27 ワシントン・ユニバーシティ プロドラッグ組成物、プロドラッグナノ粒子およびその使用方法
US20130210821A1 (en) 2010-05-27 2013-08-15 James E. Vath Methods for Treating Obesity
BR112013023056A2 (pt) * 2011-03-08 2018-10-09 Zafgen Inc derivados de oxaespiro [2,5] octano e análogos
FR2973376B1 (fr) 2011-03-28 2013-05-10 Atlanthera Derives utiles dans le traitement ou la prevention de tumeurs osseuses
TW201636342A (zh) 2014-12-19 2016-10-16 武田藥品工業有限公司 煙黴醇衍生物

Also Published As

Publication number Publication date
CO2017007189A2 (es) 2017-10-20
US20180050051A1 (en) 2018-02-22
ES2702026T3 (es) 2019-02-27
EP3233870B1 (en) 2018-10-31
TN2017000254A1 (en) 2018-10-19
SG11201704985VA (en) 2017-07-28
BR112017012965A2 (pt) 2018-01-09
US20160175332A1 (en) 2016-06-23
PH12017501134A1 (en) 2017-11-27
US9827255B2 (en) 2017-11-28
TW201636342A (zh) 2016-10-16
CL2017001602A1 (es) 2018-03-09
EP3233870A1 (en) 2017-10-25
MX2017007926A (es) 2017-09-27
IL252908A0 (en) 2017-08-31
CR20170332A (es) 2017-10-05
UY36450A (es) 2016-07-29
EA032431B1 (ru) 2019-05-31
PE20171141A1 (es) 2017-08-09
AU2015364477A1 (en) 2017-07-13
US10328089B2 (en) 2019-06-25
DOP2017000138A (es) 2017-07-31
CA2971282A1 (en) 2016-06-23
WO2016100778A1 (en) 2016-06-23
CN107207547A (zh) 2017-09-26
EA201791398A1 (ru) 2017-10-31
JP2018500329A (ja) 2018-01-11
KR20170099973A (ko) 2017-09-01
AR103078A1 (es) 2017-04-12

Similar Documents

Publication Publication Date Title
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
PE20191474A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer
CO2017006214A2 (es) Derivados de quinazolina utilizados para tratar el vih
CL2018000542A1 (es) Nuevos derivados de fenoximetilo.
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
CR20160518A (es) Compuestos para tratar atrofia muscular espinal
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
BR112016015838A8 (pt) compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação
AR094964A1 (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRASTORNOS RELACIONADOS CON LA FOSFOINOSITIDA 3-CINASA d (PI3Kd)
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
GT201700058A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
BR112019021867A2 (pt) Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenil
CU20160140A7 (es) CROMENE Y 1,1 A,2,7B- tetrahidrociclopropa[C]CROMENE PIRIDOPIRAZINEDIONES COMO MODULADORES DE GAMMA-SECRETASA
SV2016005330A (es) Compuestos de 1,3,4-tiadiazol y uso de los mismos para el tratamiento del cã�ncer
CL2019001991A1 (es) Moduladores del receptor de estrógeno.
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
CO2017003994A2 (es) Derivados de nucleósidos sustituidos con 4’-vinilo como inhibidores de la replicación del arn del virus respiratorio sincitial
CL2016002267A1 (es) Ureas asimétricas p-sustituidas y usos médicos de las mismas
CO2017009989A2 (es) Piridopirimidinonas y utilización de las mismas como moduladores de receptores de nmda
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
CU20180044A7 (es) Derivados novedosos de diamino piridina
UY35945A (es) Derivados de azaindol